Compare iShares China Large-Cap ETF (FXI) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares China Large-Cap ETF vs Summit Therapeutics Inc — how do they compare? iShares China Large-Cap ETF trades at $34.53, while Summit Therapeutics Inc trades at $13.85 (market cap $11.70B). The key difference: iShares China Large-Cap ETF is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| FXI | SMMT | |
|---|---|---|
52-Week High | $41.75 | $29.32 |
52-Week Low | $31.59 | $13.05 |
Market Cap | — | $11.70B |
Sector | — | Health |
Enterprise Value | — | $11.12B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FXI is currently trading at $34.545, up 2.29% with strong technical momentum indicated by bullish moving averages and ADX signals. The ETF benefits from China's accelerating AI and manufacturing sectors, with recent news highlighting a $295 billion AI infrastructure plan and robust export growth. However, RSI readings above 89 suggest the ETF is significantly overbought near-term.
The outlook remains positive given China's strategic investments in technology and manufacturing, though investors face risks from US-China trade tensions and potential profit-taking after recent gains. Wall Street sentiment is cautiously optimistic as institutional flows respond to China's economic initiatives.
Summit Therapeutics (SMMT) trades at $13.90, down 10.15% today, reflecting market reaction to mixed earnings and high volatility. The technical picture is bearish with weak moving averages, while fundamentals show significant losses with a net income of -$1.08B in 2025 and negative ROE/ROA. Recent news includes a $105M divestiture of ridinilazole to Biossil, sharpening focus on oncology, and upcoming Q2 2026 results on July 23, 2026.
Outlook hinges on clinical success of ivonescimab, with a bullish analyst consensus (66.7% buy ratings) and $15.57 price target suggesting 12% upside. Key risks include binary drug trial outcomes, cash burn from negative operating cash flow, and high short interest creating volatility. Investors face a high-risk, catalyst-driven opportunity dependent on pipeline execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares China Large-Cap ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The index designed to measure the performance of the largest companies in the Chinese equity market that trade on the Stock Exchange of Hong Kong and are available to international investors. The fund is non-diversified.
Read more on FXI →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
